BIT Stock Discussion
Biotron Limited Description
Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The Company is focused on the ongoing clinical development of its antiviral platform. The Company's lead antiviral drug, BIT225 is in mid-stage clinical development with approximately eight clinical trials completed. The Company has conducted clinical trails in human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and HIV-1/HCV co-infected population. The clinical trials showed that BIT225 targets and reduces levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. BIT225 has clinical antiviral activity against both HIV-1 and HCV. BIT225 is pan-genotypic and is active against all HCV genotypes, including GT3. The Company designs and develops drugs that target a class of virus protein known as viroporins. Its earlier stage programs include Dengue, Influenza and others.
Industry: Biotechnology
Keywords: Medicine Media Biotechnology Drugs Flu Clinical Trial Protein Microbiology Hepatitis Siding Virus
Recent Comments
- TRTCryptoCraig on Bad Quotes for 28 May...
- TraderMike on Bad Quotes for 28 May...
- TraderMike on Market Recap for Friday, May 31, 2024
- PleasantTurtle699 on Market Recap for Friday, May 31, 2024
- TraderMike on Market Recap for Friday, May 31, 2024
From the Blog
Featured Articles